A5080834946- Renal Transplantation Outcomes and Treatments
- Renal Diseases and Glomerulopathies
- Cytomegalovirus and herpesvirus research
- Neurological Complications and Syndromes
- Dialysis and Renal Disease Management
- Pregnancy and Medication Impact
- Folate and B Vitamins Research
- Polyomavirus and related diseases
- Metabolism and Genetic Disorders
- Systemic Lupus Erythematosus Research
- Diabetes Treatment and Management
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Pharmacological Effects and Toxicity Studies
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Viral-associated cancers and disorders
- Blood groups and transfusion
- Transplantation: Methods and Outcomes
- Vasculitis and related conditions
- Complement system in diseases
- COVID-19 Clinical Research Studies
- Organ Transplantation Techniques and Outcomes
- SARS-CoV-2 and COVID-19 Research
- Atherosclerosis and Cardiovascular Diseases
- Hemoglobinopathies and Related Disorders
Inserm
2015-2024
Centre Hospitalier Universitaire de Besançon
2015-2024
Université de franche-comté
2011-2024
Établissement Français du Sang
2009-2024
Université Bourgogne Franche-Comté
2016-2023
Université de Bourgogne
2021-2023
Fédération Hospitalo-Universitaire, Paris Center for Microbiome Medicine
2014-2022
Structure Fédérative de Recherche en Biologie et Santé de Rennes
2015-2021
Methodology and Quality of Life Unit in Oncology
2013-2019
Centre de recherche Translationnelle en Médecine moléculaire
2019
Notwithstanding the ongoing coronavirus disease-2019 (Covid-19) pandemic, information on its clinical presentation and prognosis in recipients of a kidney transplant remain scanty. The aim this registry-based observational study was to explore characteristics outcomes transplants included French nationwide Registry Solid Organ Transplant Recipients with Covid-19. Covid-19 diagnosed symptomatic patients who had positive PCR assay for SARS-CoV-2 or having typical lung lesions imaging. Clinical...
Abstract. Renal transplant recipients have disproportionately high rates of arteriosclerotic outcomes, and recent studies provided controlled evidence that clinically stable renal an excess prevalence hyperhomocysteinemia. Few suggest hyperhomocysteinemia may be a cardiovascular risk factor in recipients. In the study presented here, association between atherosclerotic events homocysteine concentrations was examined 207 The role analyzed with respect to other known cardio-vascular factors....
Background Treatment of acute antibody-mediated rejection (AMR) is based on a combination plasma exchange (PE), IVIg, corticosteroids (CS), and rituximab, but the place rituximab not clearly specified in absence randomized trials. Methods In this phase III, multicenter, double-blind, placebo-controlled trial, we randomly assigned patients with biopsy-proven AMR to receive (375 mg/m2) or placebo at day 5. All received PE, CS. The primary endpoint was composite graft loss no improvement renal...
Cytomegalovirus (CMV) drug resistance is a therapeutic challenge in the transplant setting. No longitudinal cohort studies of CMV real-life setting have been published valganciclovir era. We report findings for French multicentre prospective 346 patients enrolled at initial diagnosis infection (clinical trial registered clinicaltrials.gov: NCT01008540). Patients were monitored detection ≥2 years. Real-time by UL97 and UL54 gene sequencing antiviral phenotyping was performed if viral...
Abstract Background Patients with chronic kidney disease (CKD) are more prone to develop premature age-related diseases. Data on immune senescence scarce in CKD populations, except end-stage renal and dialysis. We designed a longitudinal prospective study evaluate at different stages its influence patient outcomes. Methods Clinical biological data collections were performed 222 patients [1–2 (n = 85), 4 53) 5 84)]. Immune biomarkers measured by cytometry T cells (CD28, CD57, CD45RA, CD31,...
Vitamin D sufficiency is associated with a reduced risk of fractures, diabetes mellitus, cardiovascular events, and cancers, which are frequent complications after renal transplantation. The VITALE (VITamin supplementation in renAL transplant recipients) study multicenter double-blind randomized trial, including nondiabetic adult recipients serum 25-hydroxy vitamin (25(OH) D) levels <30 ng/mL, 12 to 48 months transplantation receive high (100 000 IU) or low doses (12 cholecalciferol every 2...
Background. Renal transplant recipients are at increased risk of developing skin cancer. It remains difficult to establish the actual influence overimmunosuppression in development cancers. We investigated whether lymphocyte subset count may predict cancer long-term renal recipients. Methods. One hundred fifty were followed for a mean period 26 months. Each patient was examined least annually by dermatologist. Lymphocyte subsets measured annually. Results. Fifteen patients exhibited Patients...
Metabolic syndrome (MS) and obesity participate in the pathogenesis of kidney disease. We explored impact MS post-transplant weight gain on graft survival. Two hundred ninety-two renal transplant recipients (RTRs) were included study. Various parameters (e.g. anthropometric, biological) measured at time transplantation as well 1 year post-transplant. The proportion patients with overweight or significantly increased during first (p = 0.04). Mean was 2.7 +/- 5.8 kg. Thirty (10.3%) lost their...
Persistent ATG-induced CD4+ T cell lymphopenia is associated with serious clinical complications. We tested the hypothesis that ATG induces accelerated immune senescence in renal transplant recipients (RTR). Immune biomarkers were analyzed at and one-year later 97 incident RTR −62 patients receiving 35 anti-CD25 mAb (α-CD25). This consisted in: (i) thymic output; (ii) bone marrow renewal of CD34+ hematopoietic progenitor cells (CD34+HPC) lymphoid (l-HPC) myeloid (m-HPC) ratio; (iii)...
Background Previous small studies have reported favorable results of peritoneal dialysis (PD) in the setting chronic refractory heart failure (CRHF). We evaluated impact PD a larger cohort patients with CHRF where end-stage renal disease was excluded. Methods All who received therapy for CRHF between January 1995 and December 2010 two medical centers France were included this retrospective study. Baseline characteristics compared clinical parameters during first year after initiation PD....
Prolonged CD4 T cell lymphopenia after administration of polyclonal anti-thymocyte globulins increases the rate posttransplantation morbidity, but whether impaired immune reconstitution affects survival is unknown. We studied effect on in 302 consecutive prevalent renal transplant recipients and role thymic function outcomes 100 incident recipients. followed cohort for a mean duration 92 months. Of these patients, 81 (27%) had persistent counts <300/mm3 36 (12%) died during follow-up....
The natural history and clinical significance of posttransplant Epstein-Barr virus (EBV) infection remain largely unknown. aims this study are to describe the incidence, risk factors consequences EBV after kidney transplantation. A total 383 consecutive patients having received a transplant between January 2002 December 2010 were included. polymerase chain reaction (PCR) was performed every 2 weeks for 3 months, 4 next 9 months. 155 (40%) had at least one positive viremia during first year...
Some data suggest that cytomegalovirus (CMV) may be involved in atherogenesis. However, there are few suggesting CMV contribute to posttransplantation atherosclerosis. We studied a cohort of 570 consecutive renal transplant recipients. The impact on atherosclerotic events was analyzed with respect other known main cardiovascular risk factors. mean follow-up duration (±SD) 87 ± 31 months. A total 357 patients were considered exposed, and 213 naive. Cox regression analysis revealed exposure...
Data from the PEXIVAS trial challenged role of plasma exchange (PLEX) in ANCA-associated vasculitides (AAV). We aimed to describe kidney biopsy patients with AAV treated PLEX, evaluate whether histopathologic findings could predict function, and identify which would most benefit PLEX.We performed a multicenter, retrospective study on 188 AKI PLEX 237 not PLEX. The primary outcome was mortality or KRT at 12 months (M12).No significant for found. To benefitting we developed model predicting...
Background. Posttransplant diabetes mellitus (PTDM) is a frequent complication in renal-transplant recipients (RTRs). We conducted prospective study to assess the potential role of PTDM development atherosclerotic events (AE) RTRs. Methods. Three hundred fifty-seven consecutive RTRs were enrolled this study. The incidence various AE assessed with respect presence and number cardiovascular (CV) risk factors. Results. patients followed for mean duration 60±14 months. Thirty-nine (11%) had...
Metabolic syndrome (MS) is a known cardiovascular risk factor in the general population. We explored influence of MS on occurrence atherosclerotic events (AEs) after renal transplantation.Three hundred thirty-seven transplant recipients were included study. Various parameters (e.g., anthropometric and biological) measured 1 year transplant.One transplant, 32% study population met criteria for MS. Older age, male gender, pretransplant high body mass index, an increase index>or=5% first...
End-stage renal disease (ESRD) causes premature ageing of the immune system. However, it is not known whether hemodialysis (HD) and peritoneal dialysis (PD) similarly affect T cell system.The aim our study was to analyse modality may mitigate ESRD-induced senescence. We explored a large population patients (675 ESRD patients) both confirmed refined results in second cohort (84 patients).HD exhibited higher inflammatory monocytes counts (44/mm3 (1-520) vs 36/mm3 (1-161); p = 0.005). Patients...
Mycophenolate mofetil (MMF) is a new immunosuppressant developed for the prevention and treatment of acute renal rejection after transplantation. Diarrhea most frequent side effect observed during with MMF. Its pathogenic mechanisms remain unknown. We describe case severe diarrhea due to villous atrophy in transplant recipient The patient was free symptoms before Villous disappeared few months MMF withdrawal.